Alcyone Therapeutics

Focus: Alcyone Therapeutics is a gene therapy-focused biotechnology company headquartered in Lowell, Massachusetts, operating at an early clinical stage with a nascent pipeline.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Alcyone Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Alcyone Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cerebrospinal Fluid

Hydrocephaly

N/A

Clinical Trials (1)

NCT02651337Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters

N/A

Help build intelligence for Alcyone Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused gene therapy platform targeting high-unmet-need rare diseases (brainstem glioma, Batten disease)
Early-stage opportunity to shape scientific strategy and build organizational infrastructure from the ground up
Concentrated pipeline allows deep technical involvement in mechanistic and translational research

Watch Out For

Currently zero active job openings, suggesting minimal active hiring or potential organizational contraction
All programs in Phase 1/1-2 with no Phase 3 data or approved products—no near-term revenue visibility or clinical validation
Absence of public financial, employee, or funding data limits transparency on cash runway, stability, and growth trajectory

Generated by Claude from Alcyone Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ThecaFlex DRx System

Spinal Muscular Atrophy

N/A

Nusinersen

Muscular Atrophy, Spinal

Phase 1

DNX-2401

Brainstem Glioma

Phase 1

Clinical Trials (1)

NCT03178032Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Phase 1